Stockscreener 앱 받기
3.03
38.36%
0.84
시간 외 거래:
3.00
-0.03
-0.99%
Veraxa Biotech Ag 주식(VRXA)의 최신 뉴스
VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire
Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - The Globe and Mail
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -
VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView
The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance
VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa
VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang
VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times
VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire
VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times
VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan
Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire
Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to book forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
VRXA|Veraxa Biotech AG Ord Shs|Price:2.320|Chg%:-0.03 - TradingKey
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VRXA: Veraxa Biotech AGInteractive Chart - Zacks Investment Research
Enterprise value to revenue forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Veraxa Biotech Holding AG (FRA:J8L0) Stock PDF (Updated: 2026/06/26) - GuruFocus
Cash per share of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
VERAXA Biotech (VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline - Yahoo Finance
Price to sales forward of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - USA Today
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026 - MEXC
VERAXA Biotech (VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - NewMediaWire
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development - Yahoo Finance
Veraxa Biotech expands Heidelberg lab space By Investing.com - Investing.com Australia
Veraxa Biotech expands Heidelberg lab space - Investing.com UK
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development - The Manila Times
Veraxa Biotech (VRXA) CEO Antz files Form 3 with no share trades - Stock Titan
Veraxa Biotech (VRXA) director Christoph Ziegler reports 7,932 Ordinary Shares - Stock Titan
Total equity of Veraxa Biotech AG – FWB:J8L0 - TradingView
TradingKey - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:2.220|Chg%:-0.13 - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:2.350|Chg%:0.05 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
1.17%
2.48%
자본화:
|
볼륨(24시간):